ResMed Expands COPD Offering as New Data Reveals Benefits of Home Non-Invasive Ventilation
September 06 2016 - 1:00AM
Business Wire
- New research released at European
Respiratory Society (ERS) International Congress 2016 highlights
the benefits of home non-invasive ventilation (NIV), with the
potential to positively impact current practice and improve the
lives of patients with COPD
- ResMed at-home COPD management
portfolio now includes portable oxygen therapy, alongside home NIV
and remote monitoring technology
Today ResMed welcomed positive results from the independent Home
Oxygen Therapy- Home Mechanical Ventilation (HOT-HMV) study1
regarding the benefits of home non-invasive ventilation (NIV).
Portable oxygen therapy, remote monitoring technology and home NIV
are key components of ResMed’s COPD management offering.
The HOT-HMV study shows that the addition of home NIV to home
oxygen therapy improves admission-free survival in hypercapnic COPD
patients (those with high levels of carbon dioxide in the blood)
following a life-threatening exacerbation of COPD requiring acute
NIV.1 This includes an increase in patients’ median (hospital)
admission-free survival from 1.4 months in the group receiving HOT
only, to 4.3 months in the group receiving HOT plus home NIV, with
an adjusted hazard ratio of 0.49 (0.31-0.77); p=0.002.1
“These results build on and add further weight to existing
evidence supporting the broader use of home NIV in patients living
with COPD, whilst also underlining the accepted benefits of home
NIV in terms of reducing hospital admissions and improving patient
outcomes,” said Holger Woehrle, ResMed’s Vice President of Clinical
Research and Medical Director of EMEA & APAC. “We hope these
results will have a positive impact on current practice and
encourage more healthcare professionals to consider the role of
home NIV in managing their COPD patients.”
Previous studies also confirm that home NIV can successfully
reduce mortality2 and exacerbation-related hospitalisations3 and
improve patients’ quality of life.2
ResMed’s at-home COPD offering includes three series of home NIV
products, Lumis™, Stellar™ and Astral™, which can be used by COPD
patients at different stages of their disease. These solutions
ensure pulmonologists can efficiently meet the unique and
ever-changing needs of their COPD patients whilst also optimising
healthcare professionals’ time and resources.
ResMed home NIV solutions are also connected to AirView™,
ResMed’s cloud-based patient management system, which ensures
healthcare professionals can remotely identify patients in need of
attention, make informed treatment decisions and deliver timely
interventions. In addition to helping physicians better manage COPD
patients on home NIV, AirView also enables home care providers to
optimise business efficiencies and allows them to focus existing
resources on high-value activities. Resmed’s cloud-connected
ventilators provide peace of mind to patients and their families
and help improve their overall experience living with COPD.
With the ambition of improving the lives of more and more
patients, ResMed has this week unveiled the newest addition to its
growing COPD portfolio: LifeChoiceTM Activox 4LTM portable oxygen
concentrator from Inova Labs, which ResMed acquired in early 2016.
Highly portable, with class-leading battery autonomy, LifeChoice
Activox 4L is less intrusive than traditional oxygen delivery
formats. It can help COPD patients who are still mobile to overcome
the constraints that options such as tanks and Liquid O2 place on
their day-to-day activities. Specially designed for patient
comfort, this new solution also allows patients to benefit from
smoother oxygen delivery.
“COPD is a debilitating, chronic condition and we have made it
our mission as a company to help all COPD patients remain as active
and independent as they can be for as long as possible,” said Luke
Maguire, ResMed’s President of Cardio-Respiratory Care. “ResMed is
proud to take an active role in supporting our partners in the
pulmonology community to deliver new at-home technologies that can
help to achieve this across the COPD management spectrum – from
oxygen therapy, to non-invasive ventilation and remote
monitoring.”
About COPD
Chronic obstructive pulmonary disorder, or COPD, describes a
collection of lung diseases including chronic bronchitis, emphysema
and chronic obstructive airways disease. It is a progressive, fatal
condition that causes irreversible damage to the lungs and airway.
COPD leads to difficulty breathing and can have a major impact on
an individual’s quality of life. It is one of the leading causes of
death worldwide and is the only major disease that is increasing in
prevalence globally, across all continents.4,5,6 During the course
of their disease, COPD patients can experience acute exacerbations,
which manifest themselves as a sudden worsening of symptoms and can
lead to respiratory failure, hospitalisation and death. Although
the damage caused by COPD cannot be reversed, it is possible to
slow the progression of the disease through medical treatment and
lifestyle changes.
About ResMed
ResMed (NYSE:RMD) changes lives with award-winning medical
devices and cutting-edge cloud-based software applications that
better diagnose, treat and manage sleep apnoea, chronic obstructive
pulmonary disease (COPD) and other chronic diseases. ResMed is a
global leader in connected care, with more than 2 million patients
remotely monitored every day. Our 5,000-strong team is committed to
creating the world's best tech-driven medical device company –
improving quality of life, reducing the impact of chronic disease,
and saving healthcare costs in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
References
1 Murphy P. and Hart N. Home Mechanical Ventilation (HMV)
Following Life Threatening Exacerbations of COPD: A UK Multicentre
Randomised Controlled Trial. Abstract presented at the European
Respiratory Society annual congress 2016, London.
2 K�hnlein T, et al. Lancet Respir Med. 2014;2 :698-705
3 Galli J, Krahnke JS, James Mamary A, Shenoy K, Zhao H, Criner
GJ. Home non-invasive ventilation use following acute hypercapnic
respiratory failure in COPD. Respir Med. 2014
May;108(5):722-8. doi: 10.1016/j.rmed.2014.03.006. Epub 2014 Mar
20.
4 Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in
high- and low-income countries. Part I. The burden of obstructive
lung disease (BOLD) initiative. Int J Tuberc Lung Dis 2008; 12:
703–708.
5 Menezes AM, Jardim JR, Peréz-Padilla R, et al. Prevalence of
chronic obstructive pulmonary disease and associated factors: the
PLATINO Study in Sao Paulo, Brazil. Cad Saude Publica 2005; 21:
1565–1573.
6 Mehrotra A, Oluwole AM, Gordon SB. The burden of COPD in
Africa: a literature review and prospective survey of the
availability of spirometry for COPD diagnosis in Africa. Trop Med
Int Health 2009; 14: 840–848
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160905005519/en/
ResMedFor media:Christine Many-LacosteMarketing
Communications, EMEA-APACO: +33 4 26 100
243news@resmed.comorFor investors:Agnes LeeInvestor
RelationsO: +1 858-836-5971investorrelations@resmed.com
ResMed (NYSE:RMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ResMed (NYSE:RMD)
Historical Stock Chart
From Apr 2023 to Apr 2024